Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ESPR
Esperion Therapeutics, Inc.
stock NASDAQ

Market Open
Jul 2, 2026 11:36:45 AM EDT
3.16USD+0.158%(0.00)3,338,943
3.16Bid   3.17Ask   0.01Spread
Pre-market
Jul 2, 2026 9:11:30 AM EDT
3.16USD0.000%(0.00)11,575
After-hours
Jul 1, 2026 4:11:30 PM EDT
3.16USD-0.095%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
05:00PM EST  Esperion Announces Inducement Grants Under NASDAQ Listing Rule   GlobeNewswire Inc
Jan 14, 2022
07:21AM EST  Credit Suisse Maintains Neutral on Esperion Therapeutics, Lowers Price Target to $6   Benzinga
Jan 11, 2022
08:10AM EST  Esperion Sees Q4 2021 Product Revenue $12M-$12.5M   Benzinga
08:00AM EST  Unprecedented CLEAR Outcomes Trial Remains On-Track for Complete Major Adverse Cardiac Events (MACE) Accumulation in 2H 2022; Achieved 85% MACE Accumulation in December   GlobeNewswire Inc
Jan 6, 2022
08:00AM EST  Esperion (NASDAQ: ESPR) today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming virtual J.P. Morgan 40th Annual Healthcare Conference on Thursday, January 13, 2022 at 10:30 a.m. Eastern Time.   GlobeNewswire Inc
Jan 4, 2022
08:00AM EST  Esperion (NASDAQ: ESPR), today announced the appointment of Benjamin O. Looker as general counsel as of January 1, 2022. Mr. Looker will serve as a member of the Esperion executive leadership team effective immediately. In his role, Mr. Looker will lead the companys legal, compliance and ethics operations.   GlobeNewswire Inc
Dec 9, 2021
09:50PM EST  10 Biggest Price Target Changes For Thursday   Benzinga
09:44PM EST  Needham Maintains Buy on Esperion Therapeutics, Lowers Price Target to $12   Benzinga
Dec 7, 2021
04:05PM EST  Esperion Announces Closing of $225 Million Public Offering   GlobeNewswire Inc
Dec 6, 2021
08:03AM EST  10 Biggest Price Target Changes For Monday   Benzinga
07:43AM EST  Goldman Sachs Maintains Sell on Esperion Therapeutics, Lowers Price Target to $5   Benzinga
07:18AM EST  Credit Suisse Maintains Neutral on Esperion Therapeutics, Lowers Price Target to $8   Benzinga
Dec 3, 2021
02:32PM EST  Mid-Afternoon Market Update: DocuSign Drops Following Weak Revenue Forecast; Longeveron Shares Climb   Benzinga
12:03PM EST  Mid-Day Market Update: Nasdaq Dips Over 400 Points; Marvell Technology Shares Rise Following Upbeat Earnings   Benzinga
10:15AM EST  Mid-Morning Market Update: Markets Open Lower; Big Lots Issues Weak Profit Forecast   Benzinga
08:11AM EST  Esperion Late Thursday Priced 32,142,858 Share Offering At $7/Share   Benzinga
07:40AM EST  The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering   Benzinga
Dec 2, 2021
11:40PM EST  Esperion Announces Pricing of $225 Million Public Offering   GlobeNewswire Inc
05:02PM EST  Esperion Announces Proposed Public Offering; Size, Price Not Disclosed   Benzinga
05:00PM EST  Esperion Announces Proposed Public Offering   GlobeNewswire Inc
Nov 12, 2021
07:00AM EST  - Analysis of pooled Phase 3 data showed that NEXLETOL [bempedoic acid (BA)] alone lowered LDL-C levels comparable to that of a moderate- or high-intensity statin ( 30%) in nearly 1 out of 3 of patients -   GlobeNewswire Inc
Nov 2, 2021
10:54AM EDT  The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US   Benzinga
10:50AM EDT  Esperion Therapeutics Q3 EPS $(2.62) Beats $(2.79) Estimate, Sales $10.90M Miss $12.85M Estimate   Benzinga
10:41AM EDT  Earnings Scheduled For November 2, 2021   Benzinga
07:00AM EDT  Recently Announced Transformative Plan to Align Operational and Expense Structure to the Current Environment and Position for Long-Term Growth   GlobeNewswire Inc
Nov 1, 2021
04:01PM EDT  Esperion (NASDAQ: ESPR) today announced the presentation of three abstracts at the American Heart Association (AHA) Scientific Sessions 2021 taking place on November 13-15, 2021.   GlobeNewswire Inc
07:26AM EDT  Esperion Appoints Seth Fischer To Board Of Directors   RTTNews
07:00AM EDT  Esperion (NASDAQ: ESPR) today announced the appointment of Seth H.Z. Fischer as a Class III director, with a term expiring at the 2022 meeting of stockholders.   GlobeNewswire Inc
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 27, 2021
04:01PM EDT  Esperion (NASDAQ: ESPR) today announced that members of Esperions management team will participate in the upcoming Credit Suisse 30th Annual Healthcare Conference.   GlobeNewswire Inc
Oct 25, 2021
07:00AM EDT  ESPERION Announces Agreement to Exchange $15 Million in Principal   GlobeNewswire Inc
Oct 19, 2021
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021   Benzinga
05:12AM EDT  Credit Suisse Downgrades Esperion Therapeutics to Neutral, Lowers Price Target to $11   Benzinga
Oct 18, 2021
07:10AM EDT  Esperion Therapeutics to Reduce Workforce by 40%, Expects $80M of Annualized Cash Savings by 2022   Benzinga
07:00AM EDT  Optimizes organizational structure and operational processes to enable growth as the Company anticipates an inflection post the read-out of the CLEAR Outcomes trial   GlobeNewswire Inc
Oct 14, 2021
11:18AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021   Benzinga
05:59AM EDT  Morgan Stanley Downgrades Esperion Therapeutics to Underweight, Announces $11 Price Target   Benzinga
Oct 12, 2021
08:00AM EDT  Esperion (NASDAQ: ESPR), today announced it will report third quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, November 2, 2021.   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 10, 2021
08:00AM EDT  The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test   Benzinga
Sep 9, 2021
08:17AM EDT  The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization   Benzinga
Sep 7, 2021
04:01PM EDT  Esperion (NASDAQ: ESPR), the lipid management company, today announced that it will host an investor webinar on the current landscape and future directions in the treatment of elevated cholesterol on Monday, September 13, 2021 at 1:30pm Eastern Time.   GlobeNewswire Inc
Sep 1, 2021
07:32AM EDT  The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering   Benzinga
Aug 31, 2021
08:15AM EDT  The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical   Benzinga
Aug 26, 2021
08:00AM EDT  Esperion (NASDAQ: ESPR) today announced that members of Esperions management team will participate in the upcoming Morgan Stanley 19th Annual Global Healthcare Conference.   GlobeNewswire Inc
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 4, 2021
08:48AM EDT  Morgan Stanley Maintains Equal-Weight on Esperion Therapeutics, Lowers Price Target to $17   Benzinga
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
11:40AM EDT  Needham Maintains Strong Buy on Esperion Therapeutics, Lowers Price Target to $114   Benzinga
11:08AM EDT  Esperion Therapeutics S-3 Shows Registration For $250M Mixed Securities Shelf Offering   Benzinga
09:30AM EDT  Esperion Therapeutics Files For Potential Mixed Shelf Offering   Benzinga
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
07:42AM EDT  Recap: Esperion Therapeutics Q2 Earnings   Benzinga
07:06AM EDT  Esperion Therapeutics Q2 EPS $(1.67) Beats $(1.84) Estimate, Sales $40.66M Miss $42.27M Estimate   Benzinga
07:00AM EDT  ESPERION Reports Second Quarter 2021 Financial Results and   GlobeNewswire Inc
03:52AM EDT  Earnings Scheduled For August 3, 2021   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 13, 2021
08:02AM EDT  Esperion (NASDAQ: ESPR), today announced it will report second quarter 2021 financial results before the open of the U.S. financial markets on Tuesday, August 3, 2021.   GlobeNewswire Inc
Jul 1, 2021
05:00PM EDT  Esperion Announces Inducement Grants Under NASDAQ Listing Rule   GlobeNewswire Inc
Jun 28, 2021
08:00AM EDT  ESPERION (NASDAQ: ESPR), today announced the appointment of JoAnne Micale Foody, MD, FACC, FAHA as Chief Medical Officer, effective immediately. She will serve as a member of the executive team and report to Sheldon Koenig, President and Chief Executive Officer. Dr. Foody brings more than 20 years of experience in academic and preventive cardiology to ESPERION.   GlobeNewswire Inc
May 24, 2021
08:00AM EDT  Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of June.   GlobeNewswire Inc
May 23, 2021
10:25AM EDT  Notable Insider Buys Of The Past Week: AT&T, GoodRx, Opendoor Technologies And More   Benzinga
May 17, 2021
09:15AM EDT  ESPERION Appoints Sheldon Koenig As President And CEO   Benzinga
09:01AM EDT  -- Mr. Koenig has 30 years of commercial and operational experience as an accomplished leader in the cardiovascular space;previously served as ESPERION COO --   GlobeNewswire Inc
May 15, 2021
12:00PM EDT  - Patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statins and treated with NEXLETOL predicted to experience a 3.3% further absolute reduction in 10-year cardiovascular event risk compared with statins alone (p<0.0001) -   GlobeNewswire Inc
May 6, 2021
08:00AM EDT  Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May.   GlobeNewswire Inc
May 5, 2021
03:38PM EDT  Esperion Stock Plummets On Wider Than Expected Q1 Earnings Loss; Analysts Move To Sidelines   Benzinga
02:52PM EDT  Mid-Afternoon Market Update: Dow Surges 180 Points; Big 5 Sporting Goods Shares Spike Higher   Benzinga
12:17PM EDT  Mid-Day Market Update: Crude Oil Rises 1%; Esperion Therapeutics Shares Drop Following Q1 Results   Benzinga
10:26AM EDT  Mid-Morning Market Update: Markets Mostly Lower; General Motors Profit Beats Estimates   Benzinga
10:10AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 5, 2021   Benzinga
09:47AM EDT  Where Esperion Therapeutics Stands With Analysts   Benzinga
09:27AM EDT  Credit Suisse Maintains Outperform on Esperion Therapeutics, Lowers Price Target to $36   Benzinga
09:26AM EDT  Northland Capital Markets Maintains Market Perform on Esperion Therapeutics, Lowers Price Target to $24   Benzinga
08:17AM EDT  Morgan Stanley Maintains Equal-Weight on Esperion Therapeutics, Lowers Price Target to $22   Benzinga
08:00AM EDT  10 Biggest Price Target Changes For Wednesday   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
07:36AM EDT  JMP Securities Maintains Market Outperform on Esperion Therapeutics, Lowers Price Target to $111   Benzinga
06:45AM EDT  Stifel Downgrades Esperion Therapeutics to Hold, Lowers Price Target to $20   Benzinga
May 4, 2021
04:16PM EDT  Esperion Therapeutics Q1 EPS $(3.50) Misses $(2.52) Estimate, Sales $7.98M Miss $26.12M Estimate   Benzinga
04:01PM EDT  U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price   GlobeNewswire Inc
08:10AM EDT  The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data   Benzinga
Apr 28, 2021
04:05PM EDT  Esperion (NASDAQ: ESPR) today announced that, on April 23, 2021, the Compensation Committee of Esperions Board of Directors granted 21 new employees 50,991 restricted stock units (RSUs) under Esperions 2017 Inducement Equity Incentive Plan.   GlobeNewswire Inc
Apr 27, 2021
08:10AM EDT  Esperion Highlights Publication Of Rationale And Design Of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL Tablet In American Heart Journal   Benzinga
08:00AM EDT  First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy   GlobeNewswire Inc
Apr 26, 2021
04:14PM EDT  Esperion Reports $50M Investment Led By Oberland Capital   Benzinga
04:08PM EDT  Esperion Secures $50 Million Funding from Oberland Capital   GlobeNewswire Inc
04:03PM EDT  Esperion Expands Partnership with Daiichi Sankyo Group to   GlobeNewswire Inc
Apr 12, 2021
04:01PM EDT  Esperion (NASDAQ: ESPR), today announced it will report first quarter 2021 financial results after the close of the U.S. financial markets on Tuesday, May 4, 2021.   GlobeNewswire Inc
Apr 6, 2021
08:00AM EDT  Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 9:30 a.m. Eastern Time.   GlobeNewswire Inc
Mar 17, 2021
04:10PM EDT  Esperion Reports Results Of Phase 2 Study Evaluating Combo Of NEXLETOL, Ezetimibe, Atorvastatin In Patients With Hypercholesterolemia Published In 'Atherosclerosis'   Benzinga
04:05PM EDT  - Results of bempedoic acid, ezetimibe and atorvastatin triple therapy study published in March issue of Atherosclerosis -   GlobeNewswire Inc
Mar 11, 2021
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 11, 2021   Benzinga
07:24AM EST  Morgan Stanley Initiates Coverage On Esperion Therapeutics with Equal-Weight Rating, Announces Price Target of $30   Benzinga
Feb 24, 2021
05:17AM EST  Needham Maintains Strong Buy on Esperion Therapeutics, Lowers Price Target to $134   Benzinga
Feb 23, 2021
05:15PM EST  Recap: Esperion Therapeutics Q4 Earnings   Benzinga
04:08PM EST  Esperion Therapeutics Q4 EPS $(3.89) Misses $(3.76) Estimate, Sales $9.64M Miss $12.52M Estimate   Benzinga
04:01PM EST  ESPERION Reports Fourth Quarter and Full Year 2020 Financial   GlobeNewswire Inc
07:25AM EST  The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts   Benzinga
04:09AM EST  Earnings Scheduled For February 23, 2021   Benzinga
Feb 12, 2021
10:06AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 12, 2021   Benzinga
06:24AM EST  Jefferies Downgrades Esperion Therapeutics to Hold, Lowers Price Target to $30   Benzinga
06:09AM EST  Esperion 13G From Platinum Investment Shows Raised Stake In Co. From ~867K Shares To ~1.56M Shares, Or 5.61% Stake   Benzinga
Feb 9, 2021
10:10AM EST  Benzinga's Top Ratings Upgrades, Downgrades For February 9, 2021   Benzinga
08:19AM EST  Goldman Sachs Downgrades Esperion Therapeutics to Sell, Announces $24 Price Target   Benzinga
08:00AM EST  Esperion (NASDAQ: ESPR), today announced it will report fourth quarter and full year 2020 financial results after the close of the U.S. financial markets on Tuesday, February 23, 2021.   GlobeNewswire Inc
Jan 29, 2021
05:00PM EST  Esperion Announces Inducement Grants Under NASDAQ Listing Rule   GlobeNewswire Inc
Jan 15, 2021
10:07AM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 15, 2021   Benzinga
07:57AM EST  B of A Securities Downgrades Esperion Therapeutics to Neutral, Announces $35 Price Target   Benzinga
Jan 13, 2021
02:34PM EST  Mid-Afternoon Market Update: Dow Rises 75 Points; Motorsport Games Shares Spike Higher   Benzinga
06:31AM EST  Esperion Sees Q4 Preliminary Net U.S. Product Sales To Be Between $8.0 Mln And $8.5 Mln   RTTNews
06:30AM EST  Esperion Sees Q4 US Net Product Sales $8M-$8.5M; Co. Had $305M In Cash, Cash Equivalents, Investment Securities As Of Dec. 31, 2020   Benzinga
06:27AM EST  Fourth-quarter 2020 U.S. net product revenue estimated between $8.0 and $8.5 million   GlobeNewswire Inc
Dec 21, 2020
08:00AM EST  Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Tim M. Mayleben, will present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 7:30 a.m. Eastern Time.   GlobeNewswire Inc
Dec 16, 2020
10:07AM EST  Esperion Therapeutics shares were trading higher after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Combination with NUSTENDI.   Benzinga
06:28AM EST  Esperion Therapeutics Announced Swiss Approval for First-in-class Cholesterol-lowering Treatment NILEMDO and its Combination with NUSTENDI   Benzinga
04:35AM EST  Daiichi Sankyo, Esperion Report Swissmedic Approval For   RTTNews
03:21AM EST  Daiichi Sankyo, Esperion Therapeutics Announce Swissmedic Approval For NILEMDO Tablet And NUSTENDI Tablet   RTTNews
03:00AM EST  - NILEMDO (bempedoic acid) is the first oral, once-daily treatment approved in almost two decades to lower low-density lipoprotein cholesterol (LDL-C) for indicated patients -   GlobeNewswire Inc
Dec 15, 2020
07:07AM EST  ESPERION Appoints Sheldon Koenig as Chief Operating Officer   Benzinga
Nov 13, 2020
09:33AM EST  Esperion Presents Results Of Pooled Data From Four Of Phase 3 Trials At AHA 2020   RTTNews
09:16AM EST  Esperion Reports NEXLETOL Tablets Highlighted At AHA 2020 With Presentations Of Analyses Demonstrating Significant Low-Density Lipoprotein Cholesterol Lowering Vs. Placebo In Phase 3 Study Subgroups   Benzinga
09:15AM EST  - Significant mean reduction of 26.5% in LDL-C with bempedoic acid vs. placebo in pooled analysis of people who cannot tolerate statins1 -   GlobeNewswire Inc
Nov 12, 2020
06:17AM EST  Esperion Announces Pricing of Offering of $250.0 Million of   GlobeNewswire Inc
Nov 11, 2020
07:38AM EST  The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap   Benzinga
Nov 10, 2020
04:59PM EST  Esperion Plans Private Offering Of $200.0 Mln Of Convertible Senior Subordinated Notes   RTTNews
07:33AM EST  Credit Suisse Upgrades Esperion Therapeutics to Outperform   Benzinga
Nov 7, 2020
02:07PM EST  Last Week's Notable Insider Buys: Cboe, IBM, Xerox And More   Benzinga
Nov 6, 2020
05:00PM EST  Esperion (NASDAQ: ESPR) today announced that, on November 4, 2020, the Compensation Committee of Esperions Board of Directors granted 33,663 restricted stock units (RSUs) to 24 new colleagues under Esperions 2017 Inducement Equity Incentive Plan.   GlobeNewswire Inc
Nov 5, 2020
05:38AM EST  Biotech Target N V Reported Purchase of 200,000 Shares of Esperion Therapeutics @ Avg Price of $25.31/Share in Form 4 Filing on Wednesday   Benzinga
Nov 4, 2020
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
Nov 3, 2020
10:01AM EST  Esperion Therapeutics, Inc. (ESPR) shares are sliding nearly 11 percent on Tuesday morning trade as the company reported wider net loss for the third quarter from the prior year.   RTTNews
Nov 2, 2020
04:49PM EST  Recap: Esperion Therapeutics Q3 Earnings   Benzinga
04:05PM EST  Esperion Sees FY 2020 R&D Expenses Between $135M And $145M, SG&A Expenses Between $200M And $210M   Benzinga
04:04PM EST  Esperion Therapeutics Q3 EPS $(3.07) Beats $(3.41) Estimate, Sales $3.80M Miss $5.93M Estimate   Benzinga
04:01PM EST  Quarter-over-quarter Script Growth Exceeded 500 Percent for NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets   GlobeNewswire Inc
07:55AM EST  Earnings Scheduled For November 2, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 27, 2020
08:00AM EDT  Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in three upcoming virtual conferences during the month of November.   GlobeNewswire Inc
Oct 19, 2020
08:00AM EDT  Esperion (NASDAQ: ESPR), today announced it will report third quarter 2020 financial results after the close of the U.S. financial markets on Monday, November 2, 2020.   GlobeNewswire Inc
Oct 15, 2020
11:43AM EDT  B of A Securities Maintains Buy on Esperion Therapeutics, Lowers Price Target to $52   Benzinga
Oct 7, 2020
08:00AM EDT  NEXLETOL (bempedoic acid) Tablets Highlighted in EAS   GlobeNewswire Inc
Sep 28, 2020
04:07PM EDT  Esperion Launches U.S. Direct-To-Consumer Campaign To Accelerate Awareness Of NEXLETOL Tablets And Increase Awareness Of Bad Cholesterol   Benzinga
04:06PM EDT  Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate   GlobeNewswire Inc
Sep 2, 2020
08:42AM EDT  Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of September.   GlobeNewswire Inc
Aug 26, 2020
09:09AM EDT  Esperion Announces Two data Presentations Of NEXLETOL Tablet At ESC Congress 2020   Benzinga
09:07AM EDT  Esperion Announces Two Data Presentations of NEXLETOL   GlobeNewswire Inc
Aug 21, 2020
04:05PM EDT  Esperion (NASDAQ: ESPR) today announced that, on August 19, 2020, the Compensation Committee of Esperions Board of Directors granted 25,566 restricted stock units (RSUs) to 28 new colleagues under Esperions 2017 Inducement Equity Incentive Plan.   GlobeNewswire Inc
Aug 12, 2020
09:41AM EDT  Benzinga's Top Upgrades, Downgrades For August 12, 2020   Benzinga
Aug 11, 2020
08:44AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
06:58AM EDT  Esperion Therapeutics Q2 EPS $4.32 May Not Compare To $1.71 Estimate, Sales $212.24M May Not Compare To $147.97M Estimate   Benzinga
05:41AM EDT  Credit Suisse Downgrades Esperion Therapeutics to Neutral, Lowers Price Target to $45   Benzinga
Aug 10, 2020
04:06PM EDT  Esperion's Sees FY20 Research & Development Expenses To Be $135M-$145M   Benzinga
04:05PM EDT  Esperion Therapeutics Q2 EPS $4.32 May Not Compare To $1.71 Estimate, Sales $212.24M May Nt Compare To $147.97M Estimate   Benzinga
04:04PM EDT  Highest Quarterly and First Half Total Revenue in Company History with $214 million in Total YTD Revenue   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 3, 2020
07:27AM EDT  Esperion (NASDAQ: ESPR) today announced it will report second quarter 2020 financial results after the close of the U.S. financial markets on August 10, 2020. Following the release, company management will host a webcast and conference call at 4:30 p.m. ET to discuss financial results and business progress.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC